THE EFFECTS OF PRISCOL (2-BENZYL-4, 5-IMIDAZOLINE HYDROCHLORIDE) IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASES
Authors: N FRANK, J A STRAZZA, J T HELSPER
Journal: Annals of Internal Medicine (1951)

Article1 July 1951THE EFFECTS OF PRISCOL (2-BENZYL-4, 5-IMIDAZOLINE HYDROCHLORIDE) IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASESNATHAN FRANK, M.D., F.A.C.P., JOHN A. STRAZZA JR., M.D., JAMES T. HELSPER, M.D.NATHAN FRANK, M.D., F.A.C.P.Search for more papers by this author, JOHN A. STRAZZA JR., M.D.Search for more papers by this author, JAMES T. HELSPER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-35-1-19 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is the purpose of this paper to report the clinical results obtained with a new vasodilator, 2-benzyl-4, 5-imidazoline hydrochloride (Priscoline), in the treatment of 22 patients with various types of peripheral vascular disorders. In the past few years several new drugs have been added to the therapeutic armamentarium of peripheral vascular disease; these are: diethyl ether, histidine and ascorbic acid, vitamin E, dibenamine, tetraethyl ammonium and Priscoline.† We at the Jersey City Medical Center have had some experience with the last three drugs.The use of diethyl ether was reported by Katz1in 1946. He administered the drug in...Bibliography1. Katz RA(a) : Impending ischemic gangrene; new non-surgical therapeutic suggestions (preliminary report), New Orleans M. and S. J. 98: 542-555, 1946. (b) Katz, R. A.: Intravenous ether: a new approach to the therapy of arteriosclerosis, Am. Heart J. 35: 869, 1948. MedlineGoogle Scholar2. LichtensteinSewell LS: Pulmonary and cerebral fat embolism following intravenous administration of ether therapeutically, J. A. M. A. 136: 827-828, 1948. CrossrefMedlineGoogle Scholar3. WirtschafterWidmann ZTR: Elaboration of histamine in vivo in treatment of peripheral vascular disorders; preliminary report, J. A. M. A. 133: 604-605, 1947. CrossrefMedlineGoogle Scholar4. Holtz P: Histaminbildung aus Histidin durch Ascorbine Saure, Naturwissenschaften 25: 14-16, 1937. CrossrefGoogle Scholar5. FriedellDruckerPickett MJEFWJ: Histidine and ascorbic acid treatment of arteriosclerosis obliterans, J. A. M. A. 138: 1036-1039, 1948. CrossrefMedlineGoogle Scholar6. Mufson I: A new treatment for the relief of obliterative diseases of peripheral arteries, Ann. Int. Med. 29: 904-913, 1948. Google Scholar7. ShuteVogelsangSkeltonShute EVABFRWE: Influence of vitamin E on vascular disease, Surg., Gynec. and Obst. 86: 1-8, 1948. MedlineGoogle Scholar8. VogelsangShuteShute ABEVWE: Vitamin E in heart disease, M. Rec. 160: 21, 91, 163, 230, 1947. Google Scholar9. NickersonGoodman MLS: Physiological properties of a new series of sympatholytic agents, Fed. Proc. 5: 194-195, 1946. Pharmacological and physiological aspects of adrenergic blockade with special reference to dibenamine, Fed. Proc. 7: 397-398, 1948. MedlineGoogle Scholar10. HechtAnderson HHRB: Influence of dibenamine (N.N-dibenzyl-β-chloro-ethyl-amine) on certain functions of sympathetic nervous system in man, Am. J. Med. 3: 3-17, 1947. Hecht, H. H., Focht, S. F., Abildskon, J. A., Burns, T. W., and Christensen, R. O.: Further observations on the action of dibenamine in human subjects, Am. J. Med. 3: 124-125, 1947. CrossrefMedlineGoogle Scholar11. AchesonMoe GHGK: Action of tetraethylammonium ion on mammalian circulation, J. Pharmacol. and Exper. Therap. 87: 220-236, 1946. MedlineGoogle Scholar12. AchesonPereira GHSA: Blocking effect of tetraethylammonium ion on superior cervical ganglion of cat, J. Pharmacol. and Exper. Therap. 87: 273-280, 1946. MedlineGoogle Scholar13. CollerCampbellBerrySutlerLyonsMoe FARNREMRRHGK: Tetra-ethyl-ammonium as adjunct in treatment of peripheral vascular disease and other painful states, Ann. Surg. 125: 729-755, 1947. CrossrefGoogle Scholar14. SlaughterBrownWakim OLHSKG: Effects of tetraethylammonium chloride on blood flow in the extremities of man, J. Lab. and Clin. Med. 33: 743-746, 1948. MedlineGoogle Scholar15. LyonsMoeNelighHooblerCampbellBerryRennick RHGKRBSWKNRLBR: Effects of blockade of antonomic ganglia in man with tetraethylammonium; preliminary observations on its clinical application, Am. J. M. Sc. 213: 315-323, 1947. CrossrefMedlineGoogle Scholar16. DeBakeyBurchRayOchsner MEGTA: The "borrowing-lending" hemodynamic phenomenon (hemometakinesia) and its therapeutic application in peripheral vascular disturbances, Ann. Surg. 126: 850-865, 1947. CrossrefGoogle Scholar17. Pearl F: Tetraethylammonium chloride—its effect on surface temperature of extremities in peripheral vascular conditions, Ann. Surg. 128: 1092-1098, 1948. CrossrefMedlineGoogle Scholar18. FriedlickChapmanStormbury ALWPJB: Severe reaction to tetraethylammonium chloride, New England J. Med. 238: 624-630, 1948. Google Scholar19. LasserRosenthalLoewe RPNL: Death following use of tetraethylammonium chloride, J. A. M. A. 139: 153-154, 1949. CrossrefGoogle Scholar20. HartmannIsler MH: Chemische Konstitution und pharmakologische Wirksamkeit von in 2—stellung substituierten Imidazolinen, Arch. f. exper. Path. u. Pharmakol., 192: 141-154, 1939. CrossrefGoogle Scholar21. MeierMüller RR: Gefässwirkung eines neuen Imidazolin-Derivates, Schweiz. med. Wchnschr. 69: 1271-1275, 1939. Google Scholar22. Meyer RT: Ueber die "adrenalinolytische" Wirkung des Priscols (Benzylimidazolin) an den Gefässen der isolierten Hinterextremität des Kaninchens; pharmakodynamischer Vergleich mit anderen gefässerweiterenden Substanzen, Helvet. med. acta (Supp. vii) 8: 18-44, 1941. Google Scholar23. AhlquistHugginsWoodbury RPRARA: Pharmacology of benzylimidazoline (Priscol), J. Pharmacol. and Exper. Therap. 89: 271-288, 1947. MedlineGoogle Scholar24. Hatt F: Wirkung einiger neuer kreislaufaktiver Pharmika (Priscol, otrivin, Ciba 60E, und Vadil) am Starlingschen Herz-Lungen Präparat, Helvet. med. acta (Supp. vii) 8: 70-76, 1941. Google Scholar25. GrimsonReardonMarzoniHendrix KSMJFAJP: The effects of Priscol (2-benzyl-4, 5-imidazoline HCl) on peripheral vascular diseases, hypertension and circulation in patients, Ann. Surg. 127: 968-991, 1948. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication May 30, 1949.From the Medical Service and Peripheral Vascular Clinic of the Jersey City Medical Center.†Formerly marketed by the Ciba Company under the name of Priscol. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byKrankheiten der GefäßeMedical Therapy of Occlusive Arterial DiseaseMedical Management of Peripheral Arterial Occlusive Diseases 1 July 1951Volume 35, Issue 1Page: 19-38KeywordsDrugsMedical servicesPatientsPeripheral vascular diseaseVascular diseasesVasodilatorsVitamin E ePublished: 1 December 2008 Issue Published: 1 July 1951 PDF downloadLoading ...